+

WO1993016091A1 - Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux - Google Patents

Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux Download PDF

Info

Publication number
WO1993016091A1
WO1993016091A1 PCT/EP1993/000294 EP9300294W WO9316091A1 WO 1993016091 A1 WO1993016091 A1 WO 1993016091A1 EP 9300294 W EP9300294 W EP 9300294W WO 9316091 A1 WO9316091 A1 WO 9316091A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
hydrogen
halogen
alkyl
Prior art date
Application number
PCT/EP1993/000294
Other languages
German (de)
English (en)
Inventor
Dieter Herrmann
Alfred Mertens
Harald Zilch
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of WO1993016091A1 publication Critical patent/WO1993016091A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • the present invention relates to new phospholipid derivatives of nucleosides of the general formula I,
  • Rl is a straight-chain or branched, saturated or unsaturated alkyl chain with 1-20 carbon atoms, optionally one or more times by phenyl, halogen, Ci-Cg-alkoxy, Cx-Cö-alkyl mercapto, Ci-Cg-alkoxycarbonyl -, Ci-Cg-alkylsulfinyl or Cj-Cs-alkylsulfonyl groups can be substituted,
  • X represents a valence line, oxygen, sulfur, sulfinyl or sulfonyl,
  • Y has the same meaning as X, the two
  • Groups X and Y may be the same or different,
  • Z can be oxygen or sulfur
  • A can represent a methylene group or an oxygen atom
  • Nuc can be a residue derived from a nucleoside derivative
  • J. Med. Chem. 3_3, 1380 (1990) describes nucleoside conjugates of thioether lipids with cytidine diphosphate which have an antitumor effect and could be used in oncology.
  • Chem. Pharm. Bull. 1, 209 (1988) describes 5 '- (3-SN-phosphatidyl) nucleosides with antileukaemic activity and their enzymatic synthesis from the corresponding nucleosides and phosphocholines in the presence of phospholipase D with transferase activity .
  • the compounds of the present invention are new and also have valuable pharmacological properties. They are particularly suitable for the therapy and prophylaxis of infections caused by DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, Papova viruses, the varicella zoster virus or Epstein-Barr virus or RNA viruses such as toga viruses or in particular retroviruses such as the oncoviruses HTLV-I and II, as well as the lentiviruses Visna and the human immunodeficiency virus HIV-1 and 2.
  • DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, Papova viruses, the varicella zoster virus or Epstein-Barr virus or RNA viruses such as toga viruses or in particular retroviruses such as the oncoviruses HTLV-I and II, as well as the lentiviruses Visna and the human immunodeficiency virus HIV-1 and 2.
  • the compounds of the formula I appear to be particularly suitable for the treatment of the clinical manifestations of retroviral HIV infection in humans, such as persistent generalized lymphadenopathy (PGL), the advanced stage of the AIDS-related complex (ARC) and the clinical picture of AIDS.
  • PDL persistent generalized lymphadenopathy
  • ARC advanced stage of the AIDS-related complex
  • the compounds of the present invention and their pharmaceutical preparations can also be used in combination with other medicaments for the treatment and prophylaxis of the above-mentioned infections.
  • these further medicaments include agents which can be used for the treatment and prophylaxis of HIV infections or diseases accompanying this disease, such as 3 'azido-3' deoxythymidine, 2 ', 3' dideoxynucleosides such as B. 2 ', 3'-dideoxycytidine, 2', 3 '-dideoxyadenosine and 2', 3 '-dideoxy-inosine, acyclic nucleosides (z. B. Acyclovir) or non-nucleoside RT inhibitors, such as. B. HEPT, nevirapine or L-697,661 and corresponding derivatives.
  • the compounds of the present invention and the other medicament can each be administered individually, simultaneously, if appropriate in a single or two separate formulations or at different times.
  • Possible salts of the compounds of the general formula I are, in particular, alkali metal, alkaline earth metal and ammonium salts of the phosphate group.
  • Lithium, sodium and potassium salts are preferred as alkali salts.
  • Magnesium and calcium salts are particularly suitable as alkaline earth metal salts.
  • ammonium salts are understood to be salts which contain the ammonium ion, which can be substituted up to four times by alkyl radicals having 1-4 carbon atoms and / or aralkyl radicals, preferably benzyl radicals.
  • the substituents can be the same or different.
  • the compounds of the general formula I can contain basic groups, in particular amino groups, which can be converted into acid addition salts using suitable acids.
  • suitable acids for this purpose are: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, tartaric acid, citric acid, lactic acid, maleic acid or methanesulfonic acid.
  • Rj preferably denotes a straight-chain Cg-C ⁇ alkyl group which can also be substituted by a C ⁇ -Cg alkoxy or a Ci-Cs-alkyl mercapto group.
  • Ri represents in particular a decyl, undecyl, dodecyl, tridecyl or tetradecyl group.
  • Preferred Ci-Cg-alkoxy substituents of Ri are the methoxy, ethoxy, butoxy and the hexyloxy groups.
  • Ci-Cs-alkyl mercapto residue this means in particular the methyl mercapto, ethyl mercapto, propyl mercapto, butyl mercapto and hexyl mercapto residues.
  • R2 preferably means a straight chain group, which can also be substituted by a Ci-Cg-alkoxy group or a C ⁇ ⁇ Cg-alkylraercapto group.
  • R 2 represents in particular a decyl, undecyl, dodecyl, tridecyl or tetradecyl group.
  • the C 1 -C 6 -alkoxy substituents of R 2 are preferably the methoxy, ethoxy, propoxy, butoxy and the hexyloxy group.
  • R2 is substituted by a Ci-Cs-alkyl mercapto residue, this means in particular the methyl mercapto, ethyl mercapto, butyl mercapto and hexyl mercapto residue.
  • X and Y preferably represent an oxygen or sulfur atom
  • Z is preferably an oxygen atom
  • Nuc is a nucleoside derivative represented by the 5 1-position to the phosphonic acid of the lipophilic part of the Formula I is bound.
  • the following residues are suitable as nucleosides or nucleoside analogues:
  • R 3 is hydrogen or a hydroxyl group
  • R 5 each represent hydrogen or one of the radicals 4 and R 5 is halogen, a hydroxyl, a cyano or an azido group and, moreover, R 3 and R4 can represent a further bond between C-2 'and C-3',
  • Rg can be hydrogen, an alkyl chain with 1-4 carbon atoms or halogen
  • R 6 ' can be hydrogen or a benzyl or phenylthio radical
  • R 7 can be hydrogen, an alkyl chain with 1-4 carbon atoms or halogen
  • Rg can be hydrogen, an alkyl chain with 1-4 carbon atoms, halogen, or a hydroxy or an amino group
  • Rg can be hydrogen or an amino group
  • Nuc can also be of the carbocyclic type
  • nucleosides or nucleoside analogues come into question for Nuc, which differ from the known antiviral acting connections, such as. B. carbovir, HEPT, gangciclovir, AZT or acyclovir.
  • Nuc of the formula II, 4 and R 5 are preferably each hydrogen or one of the two radicals is preferably cyano, azido or halogen, such as fluorine, chlorine, bromine or iodine.
  • R 3 and R4 represent a hydrogen atom and R5 is cyano, azido or fluorine, or R5 is hydrogen and R 3 / R 4 represent a further bond between C-2 'and C-3' are particularly preferred .
  • R or R 7 preferably denote a hydrogen atom, a methyl, ethyl, propyl or butyl radical, or a halogen atom, such as fluorine, chlorine, bromine or iodine.
  • a hydrogen atom, the methyl or ethyl radical and a chlorine or bromine atom are particularly preferred.
  • the radical R 8 is preferably a hydrogen atom, a methyl, ethyl, propyl or butyl radical, an amino group or a halogen atom such as fluorine, chlorine, bromine or iodine, preferably chlorine or bromine.
  • Rio preferably means a hydrogen, fluorine, chlorine or bromine atom, a Ci-Cg-alkoxy group, in particular a methoxy-ethoxy, propoxy, butoxy or hexyloxy group, a C ⁇ Cg-alkyl mercapto group, in particular a methyl mercapto group , Ethylmercapto, butylmercapto or hexyl mercapto group, or an amino group which can be mono- or disubstituted by a C -Cg alkyl group, such as. B. the methyl, ethyl, butyl or hexyl group, by a hydroxy-C2-C 6 alkyl group, such as. B.
  • hydroxyethyl, hydroxypropyl, hydrox - butyl or hydroxyhexyl group, by a C 3 -C 5 cycloalkyl rest such as B. the cyclopropyl, cyclopentyl or cyclohexyl radical, preferably by aryl phenyl, by an aralkyl radical, such as in particular benzyl, which may also have one or more hydroxyl or methoxy groups, by Ci-Cg-alkyl groups, such as.
  • the amino group can also be substituted by a heterarylalkyl or hetaryl radical, such as in particular z.
  • a heterarylalkyl or hetaryl radical such as in particular z.
  • the heterarylalkyl radical is preferably understood to mean the thienylmethyl, furylmethyl or pyridylmethyl radical.
  • Preferred coupled nucleosides in the claimed liponucleotides of the general formula I are:
  • the compounds of general formula I can be prepared by a compound of the general formula V,
  • R3 ' represents hydrogen or a hydroxy group protected by an oxygen protective group familiar to the person skilled in the art and R 4 ' u.
  • R5 'in each case represents hydrogen, halogen, an azido, a cyano or one of the radicals 4' and R5 'is a hydroxyl group protected by an oxygen protective group familiar to the person skilled in the art, or R3' and R4 'represent a further bond and B has the meanings given, in the presence of a condensing agent such.
  • B. an optionally substituted benzenesulfonic acid chloride, preferably 2,4,6-triisopropylbenzenesulfonic acid chloride and a tert.
  • Nitrogen base e.g.
  • pyridine or lutidine in an inert solvent such as. B. toluene, or reacted directly in pyridine and, after hydrolysis, optionally cleaves the oxygen-protecting groups in accordance with the methods customary in nucleoside chemistry, or
  • R, R2, X, Y, Z and A have the abovementioned meanings, with a compound of the general formula VI or Via, in which R 3 ', R4 •, Rs' and B have the meanings given, in Presence of phospholipase D in an inert solvent, such as.
  • an inert solvent such as.
  • chloroform brings in the presence of a suitable buffer to the reaction and, if appropriate, splits off the oxygen protecting group after the reaction, in accordance with the methods customary in nucleoside chemistry.
  • the medicaments containing compounds of the formula I for the treatment of viral infections can be administered enterally or parenterally in liquid or solid form.
  • the usual forms of application are possible, such as tablets, capsules, dragees, syrups, solutions or suspensions.
  • Water is preferably used as the injection medium, which contains the additives customary for injection solutions, such as stabilizers, solubilizers and buffers.
  • additives are, for example, tartrate and citrate buffers, ethanol, complexing agents, such as ethylene-dia-tetraacetic acid and their non-toxic salts, high-molecular polymers, such as liquid polyethylene oxide for crime regulation.
  • Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules.
  • Solid carriers are, for example, starch, lactose, mannitol, methyl cellulose, talc, highly disperse silicic acids, higher molecular fatty acids, such as stearic acid, gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers, such as polyethylene glycols, etc.
  • Preparations suitable for oral applications can, if desired, contain flavoring or sweetening agents.
  • the dosage can depend on various factors, such as the mode of application, species, age or individual condition.
  • the compounds according to the invention are usually applied in amounts of 0.1-100 mg, preferably 0.2-80 mg per day and per kg of body weight. It is preferred to distribute the daily dose over 2-5 applications, 1-2 tablets with an active ingredient content of 0.5-500 mg being administered with each application.
  • the tablets can also be delayed, which reduces the number of applications per day to 1-3.
  • the active substance content of the retarded tablets can be 2 - 1000 mg.
  • the active ingredient can also be given by continuous infusion, the amounts of 5-1000 mg per day normally being sufficient.
  • the phosphoric acid (3-dodecylmercapto-1-decyloxy) -2-propyl ester was converted from the corresponding alcohol (WO 91/05558) by reaction with POCI 3 and subsequent hydrolysis produced and used as a raw product in the above reaction.
  • mice Female Balb / c mice, 6-8 weeks old (Iffa Credo), were given 0.2 ml of a virus-containing spleen supernatant per day i.p. inoculated. The animals were i.p. daily from day 0 (start: 1 h after virus inoculation) to day 13. treated with the substance to be examined in doses of 6.25 mg, 12.5 mg, 25 mg and 50 mg per kg.
  • the substances according to the invention are investigated according to the same scheme as for AZT.
  • the results obtained show that the substances examined have a dose-dependent effect on virus-related splenomegaly and can therefore be used in the therapy of retroviral infections.
  • MT2 cells were pre-incubated with the substance to be examined and infected with HIV-1 (HTLV-III-B, MOI 0.03). The supernatant was removed, replaced with medium (including substance) and incubated for 7 days.
  • HIV-1 HTLV-III-B, MOI 0.03

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés phospholipidiques de nucléosides de la formule générale (I) dans laquelle R1 représente une chaîne alkyle linéaire ou ramifiée, saturée ou non, avec 1 à 20 atomes de carbone, qui peut être éventuellement substituée une ou plusieurs fois par des groupes phényle, halogène, alcoxy C1-C6, alkylmercapto C1-C6, alconycarbonyle C1-C6, alkylsulfinyle C1-C6 ou alkylsulfonyle C1-C6, R2 représente une chaîne alkyle linéaire ou ramifiée, saturée ou non, avec 1 à 20 atomes de carbone, qui peut être éventuellement substituée une ou plusieurs fois par des groupes phényle, halogène, alcoxy C1-C6, alkylmercapto C1-C6, alcoxycarbonyle C1-C6 ou alkylsulfonyle C1-C6, X représente un trait de valence, l'oxygène, le soufre, le sulfinyle ou le sulfonyle, Y a la même notation que X, les deux groupes X et Y pouvant être identiques ou différents, Z peut être l'oxygène ou le soufre, A peut représenter un groupe méthylène ou un atome d'oxygène, Nuc peut être un reste dérivé d'un dérivé nucléosidique, ainsi que leur tautomères et leurs sels physiologiquement tolérables d'acides ou de bases inorganiques et organiques, ainsi que le procédé pour leur fabrication et les médicaments contenant ces composés, notamment pour le traitement des infections virales ou rétrovirales.
PCT/EP1993/000294 1992-02-12 1993-02-08 Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux WO1993016091A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4204032.9 1992-02-12
DE19924204032 DE4204032A1 (de) 1992-02-12 1992-02-12 Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel

Publications (1)

Publication Number Publication Date
WO1993016091A1 true WO1993016091A1 (fr) 1993-08-19

Family

ID=6451458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/000294 WO1993016091A1 (fr) 1992-02-12 1993-02-08 Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux

Country Status (3)

Country Link
AU (1) AU3453993A (fr)
DE (1) DE4204032A1 (fr)
WO (1) WO1993016091A1 (fr)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028908A2 (fr) * 1993-06-10 1994-12-22 Wake Forest University (phospho)lipides contre l'infection a virus de l'hepatite b
WO1995001362A1 (fr) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotides de desoxynucleosides, leur fabrication et leur utilisation comme medicaments antiviraux
WO1995032984A1 (fr) * 1994-05-28 1995-12-07 Boehringer Mannheim Gmbh Nouveaux esters lipidiques de monophosphates de nucleosides et leur utilisation comme medicaments immunosuppresseurs
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
US8119800B2 (en) 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38090E1 (en) * 1994-12-13 2003-04-22 Akira Matsuda 3′-substituted nucleoside derivative

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
EP0122151A2 (fr) * 1983-04-11 1984-10-17 Meito Sangyo Kabushiki Kaisha Production de dérivés phospholipidiques d'alcools primaires ou secondaires par la technique enzymatique
WO1986000309A1 (fr) * 1984-06-21 1986-01-16 Health Research Inc. Conjugues thiophospholipides d'agents antitumoraux
WO1990000555A1 (fr) * 1988-07-07 1990-01-25 Vical, Inc. Derives lipides de nucleosides anti-viraux, incorporation liposomale et procede d'utilisation
WO1992003462A1 (fr) * 1990-08-20 1992-03-05 Boehringer Mannheim Gmbh Nouveaux derives phospholipidiques de nucleosides, leur production et leur utilisation comme medicaments antiviraux

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
EP0122151A2 (fr) * 1983-04-11 1984-10-17 Meito Sangyo Kabushiki Kaisha Production de dérivés phospholipidiques d'alcools primaires ou secondaires par la technique enzymatique
WO1986000309A1 (fr) * 1984-06-21 1986-01-16 Health Research Inc. Conjugues thiophospholipides d'agents antitumoraux
WO1990000555A1 (fr) * 1988-07-07 1990-01-25 Vical, Inc. Derives lipides de nucleosides anti-viraux, incorporation liposomale et procede d'utilisation
WO1992003462A1 (fr) * 1990-08-20 1992-03-05 Boehringer Mannheim Gmbh Nouveaux derives phospholipidiques de nucleosides, leur production et leur utilisation comme medicaments antiviraux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 117, 1992, Columbus, Ohio, US; abstract no. 33825k, J.V.AMARI ET AL. 'High-Performance Liquid Chromatographic Analysis of 3'-Azido-3'-Deoxythymidine Monophosphate Diglyceride (AZT-MP-DG), an Anti-HIV Glycerophosphollipid.' Seite 489 ;Spalte 2 ; *

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US6030960A (en) * 1993-06-10 2000-02-29 Wake Forest University Method of treating hepatitis virus infections
WO1994028908A3 (fr) * 1993-06-10 1995-03-23 Univ Wake Forest (phospho)lipides contre l'infection a virus de l'hepatite b
WO1994028908A2 (fr) * 1993-06-10 1994-12-22 Wake Forest University (phospho)lipides contre l'infection a virus de l'hepatite b
US5770584A (en) * 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
WO1995001362A1 (fr) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotides de desoxynucleosides, leur fabrication et leur utilisation comme medicaments antiviraux
AU688516B2 (en) * 1994-05-28 1998-03-12 Heidelberg Pharma Holding Gmbh New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs
WO1995032984A1 (fr) * 1994-05-28 1995-12-07 Boehringer Mannheim Gmbh Nouveaux esters lipidiques de monophosphates de nucleosides et leur utilisation comme medicaments immunosuppresseurs
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US7129227B1 (en) 1994-08-29 2006-10-31 Wake Forest University Lipid analogs for treating viral infections
US7141557B2 (en) 1994-08-29 2006-11-28 Wake Forest University Lipid analogs for treating viral infections
US7294619B2 (en) 1994-08-29 2007-11-13 Wake Forest University Lipid analogs for inhibiting the activity of hepatitis B antigen
US7294621B2 (en) 1994-08-29 2007-11-13 Wake Forest University Lipid analogs for combating tumors
US7294620B2 (en) 1994-08-29 2007-11-13 Wake Forest University Lipid analogs for inhibiting HIV-1 activity
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US7638528B2 (en) 1999-10-28 2009-12-29 Wake Forest University School Of Medicine Compositions and methods for targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US8334295B2 (en) 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8119800B2 (en) 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US12152032B2 (en) 2013-10-04 2024-11-26 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
DE4204032A1 (de) 1993-08-19
AU3453993A (en) 1993-09-03

Similar Documents

Publication Publication Date Title
WO1993016091A1 (fr) Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux
WO1993016092A1 (fr) Nouveaux conjugues acide lipophosphonique-nucleosides et leur utilisation en tant que medicaments antiviraux
EP0545966B1 (fr) Nouveaux derives phospholipidiques de nucleosides, leur production et leur utilisation comme medicaments antiviraux
AT390000B (de) Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
DE69531749T2 (de) Nukleosid-Monophosphatderivate, Verfahren zu deren Herstellung sowie deren Verwendung als Immunsuppressive Arzneimittel
DE69806919T2 (de) Antivirale pyrimidin-nukleosid-analogen
DE69413529T2 (de) Antivirale verbindungen
DE69822482T2 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
DE69721339T2 (de) Monozyklische l-nukleoside, analoga und ihre anwendungen
DE3856279T2 (de) 7-Thia-Guanosin-Derivate mit antiviraler, antitumoraler, antimetastatischer und immunstimulierender Wirkung
DE3924424A1 (de) Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
DE69232070T2 (de) Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
DE3739366A1 (de) Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
DE102014112055A1 (de) Di- und Triphosphat-Propharmaka
EP0817790B1 (fr) Conjugues lipidiques specifiques de diphosphates nucleosidiques et leur utilisation comme medicaments
DE69128626T2 (de) Enzyminaktivatoren
DE68918036T2 (de) Nukleosid-Derivate.
EP0654036B1 (fr) Liponucleotides de seco-nucleosides, leur fabrication et leur utilisation comme medicaments antiviraux
DE19855963A1 (de) Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0706530A1 (fr) Liponucleotides de desoxynucleosides, leur fabrication et leur utilisation comme medicaments antiviraux
DE60020891T2 (de) Arylphosphatderivate von d4t
EP0642527B1 (fr) Analogues de phosphates nucleosides amphiphiles
DE4021006A1 (de) Pyrimidin-derivate, deren herstellung und verwendung sowie diese enthaltende arzneimittel
DE3048877A1 (de) Pyrimidinnucleosid-phosphonate, verfahren zur herstellung und sie enthaltende mittel
AT392794B (de) Verfahren zur herstellung von neuen pharmazeutisch annehmbaren estern und salzen von 3'-azido-3'-desoxythymidin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CZ FI HU JP KR NO NZ PL RO RU SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载